Teneobio, Inc.

Teneoone, Inc.

Teneotwo, Inc.

Arsenal Biosciences, Inc.

Katherine Harris

Omid Vafa

Ute Schellenberger

Nathan D Trinklein

Wim Van Schooten

Shelley Force Aldred

Duy Pham

Kevin Dang

Harbani Kaur Malik Chaudhry

Udaya Rangaswamy

Natalie Bezman

Anzhi Yao

Stephen Santoro

Aaron Cooper

Michelle Nguyen

John Gagnon

Starlynn Clarke

Omar Khan

Heather Anne N Ogana

Laura Marie Davison

Kaitlyn Loughlin

Kyle Lorentsen

Adam Litterman

Nicole Allen

Jasper Williams

Shelley Aldred Force

Anti-BCMA heavy chain-only antibodies(HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.

Anti-BCMA heavy chain-only antibodies

Anti-CD19 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD19.

Heavy chain antibodies binding to CD19

Provided herein are recombinant nucleic acids encoding chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX. Also provided are systems of chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX, cells expressing such proteins and shRNA, and methods of use thereof.

Immune cells having co-expressed shRNAS and logic gate systems

Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.

Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.

Agonistic anti-IL-2R antibodies and methods of use

Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.

Heavy chain antibodies binding to CD22

The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.

CD3 binding antibodies

The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.

Anti-BCMA heavy chain-only antibodies (HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.

Multispecific, human heavy chain antibodies (e.g., UniAbs&#x2122;) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.

Growing community of inventors

Newark, CA, United States of America

Katherine Harris